180 related articles for article (PubMed ID: 26833153)
41. P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination.
Henriksen K; Rørbo N; Rybtke ML; Martinet MG; Tolker-Nielsen T; Høiby N; Middelboe M; Ciofu O
Pathog Dis; 2019 Mar; 77(2):. PubMed ID: 30821815
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Combined Ciprofloxacin and azithromycin free and nano formulations to control biofilm producing Pseudomonas aeruginosa isolated from burn wounds.
Raouf M; Essa S; El Achy S; Essawy M; Rafik S; Baddour M
Indian J Med Microbiol; 2021 Jan; 39(1):81-87. PubMed ID: 33460732
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.
Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
Antimicrob Agents Chemother; 2011 Sep; 55(9):4469-74. PubMed ID: 21670181
[TBL] [Abstract][Full Text] [Related]
44. Pseudomonas aeruginosa biofilms in cystic fibrosis.
Høiby N; Ciofu O; Bjarnsholt T
Future Microbiol; 2010 Nov; 5(11):1663-74. PubMed ID: 21133688
[TBL] [Abstract][Full Text] [Related]
45. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N
Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of antibiotic efficacy against infections caused by planktonic or biofilm cultures of Pseudomonas aeruginosa and Klebsiella pneumoniae in Galleria mellonella.
Benthall G; Touzel RE; Hind CK; Titball RW; Sutton JM; Thomas RJ; Wand ME
Int J Antimicrob Agents; 2015 Nov; 46(5):538-45. PubMed ID: 26364845
[TBL] [Abstract][Full Text] [Related]
47. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
Fernández-Barat L; Ciofu O; Kragh KN; Pressler T; Johansen U; Motos A; Torres A; Hoiby N
J Cyst Fibros; 2017 Mar; 16(2):222-229. PubMed ID: 27651273
[TBL] [Abstract][Full Text] [Related]
48. Subinhibitory concentration of ciprofloxacin targets quorum sensing system of Pseudomonas aeruginosa causing inhibition of biofilm formation & reduction of virulence.
Gupta P; Chhibber S; Harjai K
Indian J Med Res; 2016 May; 143(5):643-51. PubMed ID: 27488009
[TBL] [Abstract][Full Text] [Related]
49. Ambroxol inhibits mucoid conversion of Pseudomonas aeruginosa and contributes to the bactericidal activity of ciprofloxacin against mucoid P. aeruginosa biofilms.
Wang W; Yu J; He Y; Wang Z; Li F
APMIS; 2016 Jul; 124(7):611-8. PubMed ID: 27102839
[TBL] [Abstract][Full Text] [Related]
50. Influence of biofilm formation in the susceptibility of Pseudomonas aeruginosa from Brazilian patients with cystic fibrosis.
Ferreira AG; Leão RS; Carvalho-Assef AP; Folescu TW; Barth AL; Marques EA
APMIS; 2010 Aug; 118(8):606-12. PubMed ID: 20666742
[TBL] [Abstract][Full Text] [Related]
51. Analysis of Pseudomonas aeruginosa PAO1 Biofilm Protein Profile After Exposure to n-Butanolic Cyclamen coum Extract Alone and in Combination with Ciprofloxacin.
Shafiei M; Abdi-Ali A; Shahcheraghi F; Vali H; Shahbani Zahiri H; Akbari Noghabi K
Appl Biochem Biotechnol; 2017 Aug; 182(4):1444-1457. PubMed ID: 28138928
[TBL] [Abstract][Full Text] [Related]
52. Incorporation of Farnesol Significantly Increases the Efficacy of Liposomal Ciprofloxacin against Pseudomonas aeruginosa Biofilms in Vitro.
Bandara HM; Herpin MJ; Kolacny D; Harb A; Romanovicz D; Smyth HD
Mol Pharm; 2016 Aug; 13(8):2760-70. PubMed ID: 27383205
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo.
Hengzhuang W; Høiby N; Ciofu O
Methods Mol Biol; 2014; 1147():239-54. PubMed ID: 24664838
[TBL] [Abstract][Full Text] [Related]
54. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis].
Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B
Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909
[TBL] [Abstract][Full Text] [Related]
55. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells.
Lashua LP; Melvin JA; Deslouches B; Pilewski JM; Montelaro RC; Bomberger JM
J Antimicrob Chemother; 2016 Aug; 71(8):2200-7. PubMed ID: 27231279
[TBL] [Abstract][Full Text] [Related]
56. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms.
Alkawash MA; Soothill JS; Schiller NL
APMIS; 2006 Feb; 114(2):131-8. PubMed ID: 16519750
[TBL] [Abstract][Full Text] [Related]
57. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS
APMIS Suppl; 1992; 28():1-79. PubMed ID: 1449848
[TBL] [Abstract][Full Text] [Related]
58. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients.
Lee B; Schjerling CK; Kirkby N; Hoffmann N; Borup R; Molin S; Høiby N; Ciofu O
APMIS; 2011 Apr; 119(4-5):263-74. PubMed ID: 21492226
[TBL] [Abstract][Full Text] [Related]
59. Naringin sensitizes the antibiofilm effect of ciprofloxacin and tetracycline against Pseudomonas aeruginosa biofilm.
Dey P; Parai D; Banerjee M; Hossain ST; Mukherjee SK
Int J Med Microbiol; 2020 Apr; 310(3):151410. PubMed ID: 32057619
[TBL] [Abstract][Full Text] [Related]
60. Determination of the spatiotemporal dependence of
Sans-Serramitjana E; Jorba M; Pedraz JL; Vinuesa T; Viñas M
Int J Nanomedicine; 2017; 12():4409-4413. PubMed ID: 28652741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
